SCHEMBL4248945

SCHEMBL4248945

Cc1nc2ccc(C=O)cc2n1C

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 3/20 0.50
LMNA P02545 1/20 0.50
CYP2A6 P11509 3/20 0.49
HDAC1 Q13547 1/20 0.46
ESRRA P11474 1/20 0.42
MAPT P10636 4/20 0.40
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNA4 P43681 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MCHR1 Q99705 1/20 0.38
POLB P06746 2/20 0.37
HPGD P15428 2/20 0.37
GAA P10253 1/20 0.37
PTK2B Q14289 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31347018 0.81 CYP2A6 (0.47) KDM4EALDH1A1CYP2A6HDAC1MAPT
SCHEMBL19763374 0.80 KDM4E (0.48) KDM4EALDH1A1LMNACYP2A6MAPT
SCHEMBL4240671 0.79 CYP2A6 (0.45) ALDH1A1CYP2A6HDAC1ESRRASMN1; SMN2
SCHEMBL4238482 0.78 CYP2A6 (0.44) CYP2A6
SCHEMBL4249453 0.78 HDAC1 (0.46) KDM4EALDH1A1LMNACYP2A6HDAC1
SCHEMBL6118351 0.77 KDM4E (0.47) KDM4EALDH1A1LMNAHDAC1ESRRA
SCHEMBL4241864 0.76 PKM (0.43) ALDH1A1CYP2A6HDAC1MAPTPOLB
SCHEMBL1104857 0.76 KDM4E (0.58) KDM4EALDH1A1LMNAESRRAMAPT
SCHEMBL26243683 0.75 CYP2A6 (0.42) KDM4EALDH1A1CYP2A6HDAC1MAPT
SCHEMBL13931443 0.74 CYP2A6 (0.41) KDM4EALDH1A1LMNACYP2A6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US disclosed
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US disclosed
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US disclosed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US disclosed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US disclosed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US disclosed
WO-2007103755-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO disclosed
EP-1718642-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-08 EP disclosed
WO-2005082901-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249599-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 KDM4E 2565/4885ALDH1A1 3962/4885LMNA 1240/4885
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS PIK3CA, BTK, PI4KA KDM4E 3686/4885ALDH1A1 1198/4885LMNA 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.